OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers

Core Insights - ModeX Therapeutics has initiated a Phase 1/2a clinical trial for MDX2004, a first-in-class trispecific antibody-fusion protein aimed at treating advanced cancers and immune disorders [1][3] - MDX2004 is designed to stimulate T cells through three signaling pathways, enhancing immune activation and potentially rejuvenating cellular immunity [2][5] - The drug targets patients with advanced solid tumors, addressing the limited treatment options and low long-term survival rates associated with current therapies [3] Company Overview - ModeX Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative multispecific biologics for cancer and infectious diseases [7] - The company utilizes a platform called ModeX Synergistic Targeting of Antibody Receptors (MSTAR) to create unique multispecific medicines that target multiple disease pathways simultaneously [6] - ModeX is a subsidiary of OPKO Health, which is a multinational biopharmaceutical and diagnostics company aiming to establish leading positions in rapidly growing markets [8] Product Details - MDX2004 is a trispecific antibody-fusion protein that targets CD3, CD28, and 4-1BB on human T cells, promoting the expansion of stem and memory T cell populations [5] - The drug aims to restore immune function in patients with underlying immune impairments due to aging, chronic diseases, infections, or chemotherapy [5] - Preclinical proof-of-concept data and clinical dose selection analyses for MDX2004 will be presented at the SITC Annual Meeting in November 2025 [4]